We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Avenue Therapeutics Gets Complete Response Letters for IV Tramadol
Avenue Therapeutics Gets Complete Response Letters for IV Tramadol
Avenue Therapeutics has a received a Complete Response Letter (CRL) from the FDA regarding its new drug application (NDA) for intravenous tramadol, meant for treating acute pain in adults.